doi:10.48130/vns-0026-0028

[1]

Rigi M, Almarzouqi SJ, Morgan ML, Lee AG. 2015. Papilledema: epidemiology, etiology, and clinical management. Eye and Brain 7:47−57

doi: 10.2147/eb.s69174

[2]

Rougier MB, Le Goff M, Korobelnik JF. 2018. Optical coherence tomography angiography at the acute phase of optic disc edema. Eye and Vision 5(1):15

doi: 10.1186/s40662-018-0109-y

[3]

Patel MD, Khushzad F, Moss HE. 2018. Comparison of cross sectional optical coherence tomography images of elevated optic nerve heads across acquisition devices and scan protocols. Eye and Vision 5(1):17

doi: 10.1186/s40662-018-0112-3

[4]

Crum OM, Kilgore KP, Sharma R, Lee MS, Spiegel MR, et al. 2020. Etiology of papilledema in patients in the eye clinic setting. JAMA Network Open 3(6):e206625

doi: 10.1001/jamanetworkopen.2020.6625

[5]

Arcani R, Pellerey M, Rouby F, Gobin N, Scapin J, et al. 2019. Amiodarone-induced optic neuropathy: a rare side effect. La Revue de Medecine Interne 40(12):826−830

doi: 10.1016/j.revmed.2019.09.001

[6]

Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, et al. 2014. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 34(7):1261−1280

doi: 10.1097/iae.0000000000000242

[7]

Xiao K, Chen X, Wu S, Zhang Y, Chen R, et al. 2025. Real-world large sample evaluation of drug-related blepharoptosis: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database. Therapeutic Advances in Drug Safety 16:20420986251371983

doi: 10.1177/20420986251371983

[8]

Arku D, Yousef C, Abraham I. 2022. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning. Expert Opinion on Drug Safety 21(10):1235−1238

doi: 10.1080/14740338.2022.2131770

[9]

Chen XD, Xiao KH, Wu SN, Wei MY, Yu CF, et al. 2025. Drug-related retinal detachment pharmacovigilance signals in the real world: evidence from the FDA Adverse Event Reporting System. Eye 39(18):3284−3293

doi: 10.1038/s41433-025-04035-2

[10]

Alder JB, Fraunfelder FT, Edwards RO, Fraunfelder FW. 1995. Levonorgestrel implants and intracranial hypertension. The New England Journal of Medicine 332(25):1720−1721

doi: 10.1056/NEJM199506223322519

[11]

Eldweik L, McClelland C, Stein JD, Blachley TS, Lee MS. 2019. Association between cycline antibiotic and development of pseudotumor cerebri syndrome. Journal of the American Academy of Dermatology 81(2):456−462

doi: 10.1016/j.jaad.2019.03.041

[12]

Martín-Begué N, Mogas E, Dod CW, Alarcón S, Clemente M, et al. 2021. Growth hormone treatment and papilledema: a prospective pilot study. Journal of Clinical Research in Pediatric Endocrinology 13(2):146−151

doi: 10.4274/jcrpe.galenos.2020.2020.0007

[13]

Bhardwaj P, Lim SY, Gruener AM. 2022. Pseudotumor cerebri syndrome secondary to lymecycline therapy. European Journal of Ophthalmology 32(3):NP102−NP104

doi: 10.1177/11206721211072373

[14]

Bababeygy SR, Repka MX, Subramanian PS. 2009. Minocycline-associated pseudotumor cerebri with severe papilledema. Journal of Ophthalmology 2009:203583

doi: 10.1155/2009/203583

[15]

Donnet A, Dufour H, Graziani N, Grisoli F. 1992. Minocycline and benign intracranial hypertension. Biomedicine & Pharmacotherapy 46(4):171−172

doi: 10.1016/0753-3322(92)90026-4

[16]

Sommer C, Lackner H, Benesch M, Sovinz P, Schwinger W, et al. 2008. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia. Annals of Hematology 87(11):887−890

doi: 10.1007/s00277-008-0521-9

[17]

Haisa T, Yoshida S, Ohkubo T, Yoshikawa K, Machida T. 1994. Primary empty sella in association with superior sagittal sinus thrombosis and dural arteriovenous malformation: case report. Journal of Neurosurgery 81(1):122−125

doi: 10.3171/jns.1994.81.1.0122

[18]

Gutkind NE, Tse DT, Johnson TE, Tse BC. 2023. Idiopathic intracranial hypertension in female-to-male transgender patients on exogenous testosterone therapy. Ophthalmic Plastic and Reconstructive Surgery 39(5):449−453

doi: 10.1097/IOP.0000000000002344

[19]

Siddiqi AI. 2011. Rituximab as a possible cause of posterior reversible encephalopathy syndrome. The Australasian Medical Journal 4(9):513−515

doi: 10.4066/AMJ.2011.627

[20]

Qureshi S, Qureshi K, Hassan A, Antonio A. 2020. Recurrent intracranial hypertension in a transgender female-to-male on testosterone therapy: a case report (5111). Neurology 94(15_supplement):5111

doi: 10.1212/wnl.94.15_supplement.5111

[21]

Nazarian SM, Jay WM. 1988. Bilateral optic neuropathy associated with amiodarone therapy. Journal of Clinical Neuro-Ophthalmology 8(1):25−28

[22]

Alshehri M, Joury A. 2020. Ocular adverse effects of amiodarone: a systematic review of case reports. Optometry and Vision Science 97(7):536−542

doi: 10.1097/opx.0000000000001534

[23]

Karti DT, Karti O, Aktert D, Gokcay F, Celebisoy N. 2017. Sildenafil-related cerebral venous sinus thrombosis and papilledema: a case report of a rare entity. Neurological Sciences 38(9):1727−1729

doi: 10.1007/s10072-017-2987-5

[24]

Satapathy J, Mishra S, Pareek D, Srija Y. 2023. Cerebral venous sinus thrombosis in a young boy after dexamethasone abuse: a rare case report. Medical Journal of Dr D Y Patil Vidyapeeth 16(5):798

doi: 10.4103/mjdrdypu.mjdrdypu_372_22

[25]

Wortsman J, Proskuriakova E, Aryal B, Khan S, Sanchez D, et al. 2023. Partially reversible bilateral papilledema in a patient using anastrozole: a case study. Cureus 15(10):e47925

doi: 10.7759/cureus.47925

[26]

Fraunfelder FT, LaBraico JM, Meyer SM. 1985. Adverse ocular reactions possibly associated with isotretinoin. American Journal of Ophthalmology 100(4):534−537

doi: 10.1016/0002-9394(85)90676-2

[27]

Yu CW, Kwok JM, Micieli JA. 2019. Resolution of papilledema associated with cyclosporine use after change to tacrolimus. BMJ Case Reports 12(11):e232725

doi: 10.1136/bcr-2019-232725

[28]

Mishra SK, Kumar A. 2020. Acute central serous chorioretinopathy—an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia. Ophthalmology Journal 5:8−11

doi: 10.5603/oj.2020.0003

[29]

Machetanz G, Grziwotz M, Semmler L, Maier M, Maegerlein C, et al. 2023. Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen. Journal of Neuromuscular Diseases 10(4):719−725

doi: 10.3233/jnd-230032

[30]

Hussein IM, Micieli JA. 2022. Tacrolimus optic neuropathy mimicking papilledema. Case Reports in Ophthalmology 13(2):361−367

doi: 10.1159/000524699

[31]

Eggers AE, Moreno H. 2002. Suggestion for another anti-epileptic drug to use for migraine prophylaxis. Headache 42(7):696−697

doi: 10.1046/j.1526-4610.2002.02165.x

[32]

O'Dea D, Handy CM, Wexler A. 2006. Ocular changes with oxaliplatin. Clinical Journal of Oncology Nursing 10(2):227−229

doi: 10.1188/06.cjon.227-229

[33]

Anandi L, Budihardja BM, Anggraini E, Ali Badjrai R, Nusanti S. 2023. The use of artificial intelligence in detecting papilledema from fundus photographs. Taiwan Journal of Ophthalmology 13(2):184−190

doi: 10.4103/tjo.tjo-d-22-00178

[34]

Shao Y, Lou Y, Gao Y, Tan G, Liu T, et al. 2025. Expert consensus on the application of artificial intelligence in neuro-ophthalmic diseases. Visual Neuroscience 42:e019

doi: 10.48130/vns-0025-0018

[35]

Olivier T, Haslam A, Prasad V. 2021. Anticancer drugs approved by the US food and drug administration from 2009 to 2020 according to their mechanism of action. JAMA Network Open 4(12):e2138793

doi: 10.1001/jamanetworkopen.2021.38793

[36]

Chiang JCB, Zahari I, Markoulli M, Krishnan AV, Park SB, et al. 2020. The impact of anticancer drugs on the ocular surface. The Ocular Surface 18(3):403−417

doi: 10.1016/j.jtos.2020.03.008

[37]

Donald Harvey R, Morgan ET. 2014. Cancer, inflammation, and therapy: effects on cytochrome P450–mediated drug metabolism and implications for novel immunotherapeutic agents. Clinical Pharmacology & Therapeutics 96(4):449−457

doi: 10.1038/clpt.2014.143

[38]

Friedman DI. 2005. Medication-induced intracranial hypertension in dermatology. American Journal of Clinical Dermatology 6(1):29−37

doi: 10.2165/00128071-200506010-00004

[39]

Angelette AL, Rando LL, Wadhwa RD, Barras AA, Delacroix BM, et al. 2023. Tetracycline-, doxycycline-, minocycline-induced pseudotumor cerebri and esophageal perforation. Advances in Therapy 40(4):1366−1378

doi: 10.1007/s12325-023-02435-y

[40]

Nguyen HV, Gilbert AL, Fortin E, Vodopivec I, Torun N, et al. 2021. Elevated intracranial pressure associated with exogenous hormonal therapy used for gender affirmation. Journal of Neuro-Ophthalmology 41(2):217−223

doi: 10.1097/WNO.0000000000000926

[41]

Sodhi M, Sheldon CA, Carleton B, Etminan M. 2018. Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 7(3):778

doi: 10.18203/2320-1770.ijrcog20180854

[42]

Guan Y, Ji L, Zheng L, Yang J, Qin Y, et al. 2022. Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions. Frontiers in Pharmacology 13:892503

doi: 10.3389/fphar.2022.892503

[43]

Zhang B, Zhou C, Lai Y, Zhang C, Zhang Y. 2025. Associated factors for steroid-induced ocular hypertension in children with systemic lupus erythematosus. Visual Neuroscience 42:e020

doi: 10.48130/vns-0025-0022

[44]

Xiao K, Lu W, Zhang X, Lin S, Wei J, et al. 2024. An integrative predictive model for orthokeratology lens decentration based on diverse metrics. Frontiers in Medicine 11:1490525

doi: 10.3389/fmed.2024.1490525